These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

422 related items for PubMed ID: 12649192

  • 21. Excision repair cross complementing-group 1: gene expression and platinum resistance.
    Altaha R, Liang X, Yu JJ, Reed E.
    Int J Mol Med; 2004 Dec; 14(6):959-70. PubMed ID: 15547660
    [Abstract] [Full Text] [Related]

  • 22. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS, Hua J, Gibb RK, Mutch DG, Herzog TJ.
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [Abstract] [Full Text] [Related]

  • 23. Proteasome inhibition suppresses cisplatin-dependent ERCC-1 mRNA expression in human ovarian tumor cells.
    Li QQ, Ding L, Reed E.
    Res Commun Mol Pathol Pharmacol; 2000 Jul; 107(5-6):387-96. PubMed ID: 11589365
    [Abstract] [Full Text] [Related]

  • 24. Synergistic effect of curcumin and cisplatin via down-regulation of thymidine phosphorylase and excision repair cross-complementary 1 (ERCC1).
    Tsai MS, Weng SH, Kuo YH, Chiu YF, Lin YW.
    Mol Pharmacol; 2011 Jul; 80(1):136-46. PubMed ID: 21493726
    [Abstract] [Full Text] [Related]

  • 25. Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair.
    Kudo K, Gavin E, Das S, Amable L, Shevde LA, Reed E.
    Oncogene; 2012 Nov 01; 31(44):4718-24. PubMed ID: 22266871
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Irofulven cytotoxicity depends on transcription-coupled nucleotide excision repair and is correlated with XPG expression in solid tumor cells.
    Koeppel F, Poindessous V, Lazar V, Raymond E, Sarasin A, Larsen AK.
    Clin Cancer Res; 2004 Aug 15; 10(16):5604-13. PubMed ID: 15328203
    [Abstract] [Full Text] [Related]

  • 28. Effect of interleukin-1 alpha and tumour necrosis factor-alpha on cisplatin-induced ERCC-1 mRNA expression in a human ovarian carcinoma cell line.
    Li Q, Bostick-Bruton F, Reed E.
    Anticancer Res; 1998 Aug 15; 18(4A):2283-7. PubMed ID: 9703867
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Adenoviral delivery of A-FOS, an AP-1 dominant negative, selectively inhibits drug resistance in two human cancer cell lines.
    Bonovich M, Olive M, Reed E, O'Connell B, Vinson C.
    Cancer Gene Ther; 2002 Jan 15; 9(1):62-70. PubMed ID: 11916245
    [Abstract] [Full Text] [Related]

  • 33. Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinum-based anticancer agents.
    Youn CK, Kim MH, Cho HJ, Kim HB, Chang IY, Chung MH, You HJ.
    Cancer Res; 2004 Jul 15; 64(14):4849-57. PubMed ID: 15256455
    [Abstract] [Full Text] [Related]

  • 34. Suppression of ovarian cancer cell tumorigenicity and evasion of Cisplatin resistance using a truncated epidermal growth factor receptor in a rat model.
    Chan JK, Pham H, You XJ, Cloven NG, Burger RA, Rose GS, Van Nostrand K, Korc M, Disaia PJ, Fan H.
    Cancer Res; 2005 Apr 15; 65(8):3243-8. PubMed ID: 15833856
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair.
    Yang LY, Li L, Jiang H, Shen Y, Plunkett W.
    Clin Cancer Res; 2000 Mar 15; 6(3):773-81. PubMed ID: 10741696
    [Abstract] [Full Text] [Related]

  • 38. Ormaplatin sensitivity/resistance in human ovarian cancer cells made resistant to cisplatin.
    Parker RJ, Vionnet JA, Bostick-Bruton F, Reed E.
    Cancer Res; 1993 Jan 15; 53(2):242-7. PubMed ID: 8417816
    [Abstract] [Full Text] [Related]

  • 39. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.
    Kozubík A, Horváth V, Svihálková-Sindlerová L, Soucek K, Hofmanová J, Sova P, Kroutil A, Zák F, Mistr A, Turánek J.
    Biochem Pharmacol; 2005 Feb 01; 69(3):373-83. PubMed ID: 15652229
    [Abstract] [Full Text] [Related]

  • 40. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
    Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, Viñolas N, Paz-Ares L, Lopez-Vivanco G, Muñoz MA, Felip E, Alberola V, Camps C, Domine M, Sanchez JJ, Sanchez-Ronco M, Danenberg K, Taron M, Gandara D, Rosell R.
    J Clin Oncol; 2007 Jul 01; 25(19):2747-54. PubMed ID: 17602080
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.